Today: 28 February 2026
Subscribe
Browse Category

EPA:ABVX 16 December 2025 - 22 December 2025

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

Abivax shares jumped as much as 14% to €114.4 in Paris on Monday after reports of renewed takeover interest from Eli Lilly and the company’s addition to the Nasdaq Biotechnology Index. French outlet La Lettre reported Lilly representatives met with French Treasury officials this month about a potential deal, though Reuters said it could not confirm the meeting. Neither company commented on the rumors.
22 December 2025
··
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

Abivax shares fell about 5% in U.S. and Paris trading after reporting a nine-month net loss of €254.1 million, up from €136.9 million a year earlier. Cash and cash equivalents stood at €589.7 million as of September 30, expected to fund operations into Q4 2027. Investors weighed widening losses against a strong cash position and ongoing takeover speculation.
16 December 2025
···
Go toTop